FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i>-Mutated Metastatic Castrate-Resistant Prostate Cancer
Mitchell S. Anscher, Julia A. Beaver(Center for Drug Evaluation and Research), Erik Bloomquist(Center for Drug Evaluation and Research), Karen E. Bijwaard(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Soma Ghosh(Center for Devices and Radiological Health), Ann Marie Trentacosti(United States Food and Drug Administration), Shaily Arora(United States Food and Drug Administration), Reena Philip(Center for Devices and Radiological Health), Maritsa Serlemitsos-Day(United States Food and Drug Administration), Ning Yang(United States Food and Drug Administration), Frances Fahnbulleh(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Barbara K. Fuller(United States Food and Drug Administration), Pamela Gallagher(Center for Devices and Radiological Health), Richard Pazdur(United States Food and Drug Administration), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Kirsten B. Goldberg(United States Food and Drug Administration), Ruth Mayrosh(United States Food and Drug Administration), Elaine Chang(Center for Drug Evaluation and Research), Chana Weinstock(United States Food and Drug Administration), Oluseyi Adeniyi(United States Food and Drug Administration), Xin Gao(Center for Drug Evaluation and Research), Sarah Zimmerman(United States Food and Drug Administration), Rosane Charlab, Yutao Gong(Center for Drug Evaluation and Research), Felicia Diggs(United States Food and Drug Administration)
Cited by 74
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k